Iterum Therapeutics (ITRM) Short Interest Ratio & Short Volume $1.63 +0.11 (+7.24%) (As of 11/20/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Iterum Therapeutics Short Interest DataIterum Therapeutics (ITRM) has a short interest of 2.53 million shares, representing 11.53% of the float (the number of shares available for trading by the public). This marks a 1,082.80% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.1, indicating that it would take 1.1 days of the average trading volume of 954,633 shares to cover all short positions.Current Short Interest2,530,000 sharesPrevious Short Interest213,900 sharesChange Vs. Previous Month+1,082.80%Dollar Volume Sold Short$3.26 millionShort Interest Ratio1.1 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares27,516,000 sharesFloat Size21,950,000 sharesShort Percent of Float11.53%Today's Trading Volume1,038,605 sharesAverage Trading Volume954,633 sharesToday's Volume Vs. Average109% Short Selling Iterum Therapeutics? Sign up to receive the latest short interest report for Iterum Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartITRM Short Interest Over TimeITRM Days to Cover Over TimeITRM Percentage of Float Shorted Over Time Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Iterum Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20242,530,000 shares $3.26 million +1,082.8%11.5%1.1 $1.29 10/15/2024213,900 shares $218,178.00 -0.7%1.0%0.7 $1.02 9/30/2024215,300 shares $234,677.00 -37.0%1.0%0.7 $1.09 9/15/2024341,700 shares $372,453.00 +53.4%1.6%1.1 $1.09 8/31/2024222,800 shares $262,904.00 -49.8%1.0%0.8 $1.18 8/15/2024443,600 shares $541,192.00 -80.5%2.1%1.9 $1.22 Get the Latest News and Ratings for ITRM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/20242,270,000 shares $2.70 million +24.7%14.0%11.1 $1.19 7/15/20241,820,000 shares $2.88 million +42.2%11.2%10.3 $1.58 6/30/20241,280,000 shares $1.47 million +0.8%7.9%9.9 $1.15 6/15/20241,270,000 shares $1.46 million +2.4%7.8%9.1 $1.15 5/31/20241,240,000 shares $1.86 million -0.8%7.6%8.5 $1.50 5/15/20241,250,000 shares $1.86 million +0.8%7.7%7.7 $1.49 4/30/20241,240,000 shares $1.90 million +3.3%7.7%6.4 $1.53 4/15/20241,200,000 shares $1.85 million -2.4%7.5%2 $1.54 3/31/20241,230,000 shares $1.89 million +1.7%9.4%2.1 $1.54 3/15/20241,210,000 shares $1.77 million +24.1%9.3%2.1 $1.46 2/29/2024975,300 shares $1.21 million -16.6%7.5%1.7 $1.24 2/15/20241,170,000 shares $1.76 million +2,132.8%8.9%2 $1.50 1/31/202452,400 shares $80,696.00 +9.4%0.4%0.1 $1.54 1/15/202447,900 shares $88,136.00 -70.8%0.4%0.3 $1.84 12/31/2023164,100 shares $323,277.00 -17.1%1.3%1.1 $1.97 12/15/2023198,000 shares $352,440.00 -8.2%1.5%1.4 $1.78 11/30/2023215,700 shares $405,516.00 +258.9%1.7%1.7 $1.88 11/15/202360,100 shares $52,587.50 +22.9%0.5%0.7 $0.88 10/31/202348,900 shares $31,956.15 +0.6%0.4%1.5 $0.65 10/15/202348,600 shares $36,936.00 -16.2%0.4%1.3 $0.76 9/30/202358,000 shares $46,458.00 +6.6%0.5%1.5 $0.80 9/15/202354,400 shares $43,465.60 -2.9%0.4%1.4 $0.80 8/31/202356,000 shares $49,946.40 -34.7%0.4%1.4 $0.89 8/15/202385,700 shares $83,129.00 +72.8%0.7%1.7 $0.97 7/31/202349,600 shares $51,584.00 -29.9%0.4%1 $1.04 7/15/202370,800 shares $83,544.00 +10.8%0.6%1.4 $1.18 6/30/202363,900 shares $68,373.00 -5.8%0.5%1.2 $1.07 6/15/202367,800 shares $75,936.00 +5.4%0.5%1.2 $1.12 5/31/202364,300 shares $73,945.00 -5.7%0.5%0.9 $1.15 5/15/202368,200 shares $77,195.58 -10.7%0.5%1 $1.13 4/30/202376,400 shares $89,388.00 -26.5%0.6%1.2 $1.17 4/15/2023103,900 shares $122,602.00 -0.5%0.8%1.5 $1.18 3/31/2023104,400 shares $104,389.56 -32.4%0.8%1.3 $1.00 3/15/2023154,400 shares $154,400.00 -15.5%1.2%1.5 $1.00Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide 2/28/2023182,700 shares $208,278.00 -14.9%1.5%0.5 $1.14 2/15/2023214,700 shares $266,228.00 -31.4%1.8%0.6 $1.24 1/31/2023312,800 shares $434,792.00 -12.0%2.6%0.9 $1.39 1/15/2023355,300 shares $426,360.00 +23.3%3.0%1 $1.20 12/30/2022288,200 shares $242,088.00 +106.0%2.4%0.9 $0.84 12/15/2022139,900 shares $169,279.00 -29.7%1.2%0.4 $1.21 11/30/2022199,100 shares $258,830.00 -8.4%1.7%3.6 $1.30 11/15/2022217,400 shares $315,230.00 +85.0%1.8%3.1 $1.45 10/31/2022117,500 shares $198,575.00 -42.6%1.0%1.4 $1.69 10/15/2022204,800 shares $337,920.00 +17.7%1.7%2.2 $1.65 9/30/2022174,000 shares $281,880.00 +11.8%1.5%0.6 $1.62 9/15/2022155,600 shares $311,200.00 -20.3%1.3%0.5 $2.00 8/31/2022195,300 shares $515,592.00 +73.5%1.6%0.7 $2.64 8/15/2022112,600 shares $472,920.00 -96.6%1.3%0.4 $4.20 7/31/20223,280,000 shares $721,600.00 -19.4%1.8%0.8 $0.22 7/15/20224,070,000 shares $1.09 million +27.6%2.3%1 $0.27 6/30/20223,190,000 shares $638,638.00 +38.7%1.8%0.9 $0.20 6/15/20222,300,000 shares $476,100.00 +9.0%1.3%2 $0.21 5/31/20222,110,000 shares $485,300.00 -22.4%1.2%1.9 $0.23 5/15/20222,720,000 shares $594,592.00 -34.9%1.5%2.3 $0.22 4/30/20224,180,000 shares $1.06 million +56.6%2.3%3.5 $0.25 4/15/20222,670,000 shares $819,423.00 -24.8%1.5%1.9 $0.31 3/31/20223,550,000 shares $1.26 million +27.2%N/A2.4 $0.36 3/15/20222,790,000 shares $962,550.00 -0.4%1.6%1.6 $0.35 2/28/20222,800,000 shares $1.12 million -15.9%1.6%1.5 $0.40 2/15/20223,330,000 shares $1.34 million -37.2%1.9%1.5 $0.40 1/31/20225,300,000 shares $1.82 million +6.4%3.0%1.9 $0.34 1/15/20224,980,000 shares $1.94 million +25.1%N/A1.1 $0.39 12/31/20213,980,000 shares $1.56 million -5.0%2.2%0.9 $0.39 12/15/20214,190,000 shares $2.07 million +25.8%2.4%0.8 $0.50 11/30/20213,330,000 shares $1.64 million -38.7%1.9%0.6 $0.49 11/15/20215,430,000 shares $3.00 million +26.9%3.1%1 $0.55 10/29/20214,280,000 shares $2.29 million +34.2%2.4%0.8 $0.53 10/15/20213,190,000 shares $1.76 million +132.9%1.8%0.6 $0.55 9/30/20211,370,000 shares $765,008.00 -18.5%0.8%0.2 $0.56 9/15/20211,680,000 shares $1.01 million -34.6%1.0%0.2 $0.60 8/31/20212,570,000 shares $1.72 million -45.1%1.5%0.2 $0.67 8/13/20214,680,000 shares $3.26 million -4.3%2.6%0.3 $0.70 7/30/20214,890,000 shares $3.81 million +35.5%2.8%0.3 $0.78 7/15/20213,610,000 shares $4.12 million -1.1%2.1%0.3 $1.14 6/30/20213,650,000 shares $8.43 million -8.3%2.1%0.3 $2.31 6/15/20213,980,000 shares $7.60 million +36.8%2.3%0.4 $1.91 5/28/20212,910,000 shares $4.22 million +56.5%1.7%0.3 $1.45 5/14/20211,860,000 shares $1.80 million -47.6%N/A0.2 $0.97 4/30/20213,550,000 shares $4.22 million -21.8%N/A0.2 $1.19 4/15/20214,540,000 shares $5.31 million +14.4%N/A0.2 $1.17 3/31/20213,970,000 shares $5.64 million -24.7%N/A0.1 $1.42 3/15/20215,270,000 shares $8.17 million +45.2%N/A0.2 $1.55 2/26/20213,630,000 shares $6.35 million -4.5%N/A0.2 $1.75 2/12/20213,800,000 shares $8.93 million +106.5%N/A0.2 $2.35Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide 1/29/20211,840,000 shares $2.63 million -69.3%N/A0.1 $1.43 1/15/20216,000,000 shares $7.20 million +2.2%N/A0.7 $1.20 12/31/20205,870,000 shares $5.59 million +26.8%N/A1 $0.95 12/15/20204,630,000 shares $4.49 million +701.7%N/A0.5 $0.97 11/30/2020577,500 shares $440,401.50 +77.2%N/A0.1 $0.76 11/15/2020325,900 shares $169,468.00 +14.6%N/A0.1 $0.52 10/30/2020284,500 shares $139,063.60 -65.7%N/A0.1 $0.49 10/15/2020830,100 shares $787,764.90 +355.4%6.0%0.2 $0.95 9/30/2020182,300 shares $191,415.00 +0.2%1.3%0 $1.05 9/15/2020182,000 shares $114,678.20 -4.8%1.3%0.3 $0.63 8/31/2020191,100 shares $149,058.00 -14.5%1.4%0.2 $0.78 8/14/2020223,400 shares $201,060.00 +5.6%1.6%0.2 $0.90 7/31/2020211,500 shares $219,960.00 -48.5%1.5%0.2 $1.04 7/15/2020410,700 shares $435,342.00 +6.8%3.0%0.3 $1.06 6/30/2020384,700 shares $546,274.00 +4.9%3.6%0.4 $1.42 6/15/2020366,900 shares $565,026.00 -18.2%4.1%0.5 $1.54 5/29/2020448,600 shares $1.93 million +32.9%5.7%0.7 $4.31 5/15/2020337,500 shares $1.16 million +8.9%5.6%3.9 $3.44 4/30/2020309,900 shares $1.08 million +5.4%5.1%6.1 $3.50 4/15/2020294,100 shares $808,775.00 -21.8%4.8%5.2 $2.75 3/31/2020376,000 shares $1.00 million -14.0%6.4%4.7 $2.67 3/13/2020437,200 shares $1.26 million -15.0%7.4%9.2 $2.89 2/28/2020514,300 shares $966,884.00 -5.8%8.7%1.7 $1.88 2/14/2020545,900 shares $1.12 million -2.9%9.2%1.8 $2.05 1/31/2020562,400 shares $1.65 million +159.9%9.5%1.8 $2.93 1/15/2020216,400 shares $553,984.00 -35.7%3.2%0.7 $2.56 12/31/2019336,400 shares $925,100.00 +21.3%5.0%1.2 $2.75 ITRM Short Interest - Frequently Asked Questions What is Iterum Therapeutics' current short interest? Short interest is the volume of Iterum Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 2,530,000 shares of ITRM short. 11.53% of Iterum Therapeutics' shares are currently sold short. Learn More on Iterum Therapeutics' current short interest. What is a good short interest ratio for Iterum Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ITRM shares currently have a short interest ratio of 1.0. Learn More on Iterum Therapeutics's short interest ratio. What is a good short interest percentage for Iterum Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.53% of Iterum Therapeutics' floating shares are currently sold short. Is Iterum Therapeutics' short interest increasing or decreasing? Iterum Therapeutics saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 2,530,000 shares, an increase of 1,082.8% from the previous total of 213,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Iterum Therapeutics' float size? Iterum Therapeutics currently has issued a total of 27,516,000 shares. Some of Iterum Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Iterum Therapeutics currently has a public float of 21,950,000 shares. How does Iterum Therapeutics' short interest compare to its competitors? 11.53% of Iterum Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Iterum Therapeutics: Spero Therapeutics, Inc. (1.15%), Inozyme Pharma, Inc. (7.40%), Kyverna Therapeutics, Inc. (13.71%), Caribou Biosciences, Inc. (12.43%), Galectin Therapeutics Inc. (12.76%), Nkarta, Inc. (13.56%), Tenaya Therapeutics, Inc. (7.99%), DiaMedica Therapeutics Inc. (0.41%), Heron Therapeutics, Inc. (18.94%), Adaptimmune Therapeutics plc (2.09%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Iterum Therapeutics stock? Short selling ITRM is an investing strategy that aims to generate trading profit from Iterum Therapeutics as its price is falling. ITRM shares are trading up $0.11 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Iterum Therapeutics? A short squeeze for Iterum Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ITRM, which in turn drives the price of the stock up even further. How often is Iterum Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ITRM, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Spero Therapeutics Short Interest Inozyme Pharma Short Interest Kyverna Therapeutics Short Interest Caribou Biosciences Short Interest Nkarta Short Interest Tenaya Therapeutics Short Interest Galectin Therapeutics Short Interest DiaMedica Therapeutics Short Interest MediWound Short Interest Adaptimmune Therapeutics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ITRM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
